NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) today announced that Hyung Heon Kim, President and Chief Executive Officer, and Robert Homolka, Senior Vice-President of Clinical Operations, will present a company overview at the H.C. Wainwright 7th Annual NASH Investor Conference on Tuesday, October 24th at 2:30 pm ET.
|
[17-October-2023] |
BOSTON, Oct. 17, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, and Robert Homolka, Senior Vice-President of Clinical Operations, will present a company overview at the H.C. Wainwright 7th Annual NASH Investor Conference on Tuesday, October 24th at 2:30 pm ET. Mr. Kim and Mr. Homolka will also be available for virtual one-on-one meetings during the event. Institutional investors who are registered for the conference can request a meeting through the conference platform. A live webcast of Mr. Kim’s and Mr. Homolka’s presentation will be available on the Event Calendar page of the NeuroBo website at: https://www.neurobopharma.com/events-presentations/event-calendar. An archived replay will be available on the company’s website for a period of 90 days after the conference. About NeuroBo Pharmaceuticals Contact: Rx Communications Group
View original content:https://www.prnewswire.com/news-releases/neurobo-to-present-at-the-hc-wainwright-7th-annual-nash-investor-conference-301958428.html SOURCE NeuroBo Pharmaceuticals, Inc. | ||
Company Codes: NASDAQ-NMS:NRBO |